Impaired bone health is among the most significant long-term consequences of hematopoietic stem cell transplantation (HSCT), a common therapy for patients with malignant and non-malignant hematological diseases.
To address this serious problem, the International Osteoporosis Foundation (IOF) expert Working Group on Cancer and Bone Disease has published a new Executive Summary of its authoritative state-of-the-art review. The review outlined the major factors affecting bone health in HSCT patients, what do they test for accutane and provided expert guidance for the monitoring, evaluation and treatment of bone loss in these patients. Published in the Journal of Bone Oncology, the Executive Summary now provides a helpful management algorithm and succinct key guidance based on the Working Group’s expert opinion.
Professor René Rizzoli, Chair of the IOF Cancer and Bone Working Group and Emeritus Professor of Medicine at the University Hospitals of Geneva, Switzerland, stated:
“This concise summary aims to encourage and assist hematologists and oncologists in addressing osteoporosis and fracture prevention in their hematopoietic stem cell transplantation patients. The ‘check list’ includes bone mineral density examination, evaluation of clinical risk factors, and general dietary and physical activity measures, with appropriate application of osteoporosis pharmacotherapies in those who are found to be at increased high risk of fracture.”
Professor Nicholas Harvey, Chair of the IOF Committee of Scientific Advisors and Professor of Rheumatology and Clinical Epidemiology at the MRC Lifecourse Epidemiology Unit, University of Southampton, UK added:
Source: Read Full Article